-
Something wrong with this record ?
Bilirubin Down-Regulates Oxidative Stress and Fibroblast Growth Factor 23 Expression in UMR106 Osteoblast-Like Cells
S. Rausch, K. Hammerschmidt, M. Feger, L. Vítek, M. Föller
Language English Country Germany
Document type Journal Article
PubMed
38373702
DOI
10.1055/a-2237-8863
Knihovny.cz E-resources
- MeSH
- Bilirubin * pharmacology MeSH
- Fibroblast Growth Factors MeSH
- Fibroblast Growth Factor-23 * MeSH
- Phosphates metabolism MeSH
- Osteoblasts MeSH
- Oxidative Stress MeSH
- Vitamin D MeSH
- Publication type
- Journal Article MeSH
INTRODUCTION: Fibroblast growth factor 23 (FGF23) is a major regulator of phosphate and vitamin D metabolism in the kidney, and its higher levels in plasma are associated with poorer outcomes in kidney and cardiovascular diseases. It is produced by bone cells upon enhanced oxidative stress and inhibits renal phosphate reabsorption and calcitriol (active form of vitamin D) production. Bilirubin, the final product of the heme catabolic pathway in the vascular bed, has versatile biological functions, including antioxidant and anti-inflammatory effects. This study explored whether bilirubin alters FGF23 production. METHODS: Experiments were performed using UMR106 osteoblast-like cells. Fgf23 transcript levels were determined by quantitative real-time polymerase chain reaction, C-terminal and intact FGF23 protein levels were determined by enzyme-linked immunosorbent assay, and cellular oxidative stress was assessed by CellROX assay. RESULTS: Unconjugated bilirubin down-regulated Fgf23 gene transcription and FGF23 protein abundance; these effects were paralleled by lower cellular oxidative stress levels. Also, conjugated bilirubin reduced Fgf23 mRNA abundance. CONCLUSION: Bilirubin down-regulates FGF23 production in UMR106 cells, an effect likely to be dependent on the reduction of cellular oxidative stress.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007234
- 003
- CZ-PrNML
- 005
- 20240423155819.0
- 007
- ta
- 008
- 240412s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1055/a-2237-8863 $2 doi
- 035 __
- $a (PubMed)38373702
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Rausch, Steffen $u University of Hohenheim, Department of Physiology, Stuttgart, Germany
- 245 10
- $a Bilirubin Down-Regulates Oxidative Stress and Fibroblast Growth Factor 23 Expression in UMR106 Osteoblast-Like Cells / $c S. Rausch, K. Hammerschmidt, M. Feger, L. Vítek, M. Föller
- 520 9_
- $a INTRODUCTION: Fibroblast growth factor 23 (FGF23) is a major regulator of phosphate and vitamin D metabolism in the kidney, and its higher levels in plasma are associated with poorer outcomes in kidney and cardiovascular diseases. It is produced by bone cells upon enhanced oxidative stress and inhibits renal phosphate reabsorption and calcitriol (active form of vitamin D) production. Bilirubin, the final product of the heme catabolic pathway in the vascular bed, has versatile biological functions, including antioxidant and anti-inflammatory effects. This study explored whether bilirubin alters FGF23 production. METHODS: Experiments were performed using UMR106 osteoblast-like cells. Fgf23 transcript levels were determined by quantitative real-time polymerase chain reaction, C-terminal and intact FGF23 protein levels were determined by enzyme-linked immunosorbent assay, and cellular oxidative stress was assessed by CellROX assay. RESULTS: Unconjugated bilirubin down-regulated Fgf23 gene transcription and FGF23 protein abundance; these effects were paralleled by lower cellular oxidative stress levels. Also, conjugated bilirubin reduced Fgf23 mRNA abundance. CONCLUSION: Bilirubin down-regulates FGF23 production in UMR106 cells, an effect likely to be dependent on the reduction of cellular oxidative stress.
- 650 12
- $a fibroblastový růstový faktor 23 $7 D000089703
- 650 12
- $a bilirubin $x farmakologie $7 D001663
- 650 _2
- $a fibroblastové růstové faktory $7 D005346
- 650 _2
- $a osteoblasty $7 D010006
- 650 _2
- $a fosfáty $x metabolismus $7 D010710
- 650 _2
- $a oxidační stres $7 D018384
- 650 _2
- $a vitamin D $7 D014807
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hammerschmidt, Katharina $u University of Hohenheim, Department of Physiology, Stuttgart, Germany
- 700 1_
- $a Feger, Martina $u University of Hohenheim, Department of Physiology, Stuttgart, Germany
- 700 1_
- $a Vítek, Libor $u Fourth Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Föller, Michael $u University of Hohenheim, Department of Physiology, Stuttgart, Germany
- 773 0_
- $w MED00009707 $t Experimental and clinical endocrinology & diabetes $x 1439-3646 $g Roč. 132, č. 2 (2024), s. 91-97
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38373702 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155816 $b ABA008
- 999 __
- $a ok $b bmc $g 2081304 $s 1217001
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 132 $c 2 $d 91-97 $e 20240219 $i 1439-3646 $m Experimental and clinical endocrinology & diabetes $n Exp Clin Endocrinol Diabetes $x MED00009707
- LZP __
- $a Pubmed-20240412